Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 44

Sort by

Sort Order Select

Meeting Abstracts

756-P: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Endoscopy Failure or Aspiration—A Cohort Study

WAJD ALKABBANI, KARINE SUISSA, KRISTINE D. GU, SARA JANE CROMER, JULIE M. PAIK, KATSIARYNA BYKOV, ION HOBAI, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):756-P

https://doi.org/10.2337/db24-756-P

Published: 14 June 2024

View article titled, 756-P: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Endoscopy Failure or Aspiration—A Cohort Study

Meeting Abstracts

1409-P: Changing Trends in Glucose-Lowering Drug Initiation for Type 2 Diabetes in the Era of Tirzepatide

ELISABETTA PATORNO, HELEN TESFAYE, JANINNE ORTEGA-MONTIEL, CAROLINE ALIX, ELYSE C. DICESARE, SARA JANE CROMER, DEBORAH J. WEXLER, JULIE M. PAIK

Diabetes 2024;73(Supplement_1):1409-P

https://doi.org/10.2337/db24-1409-P

Published: 14 June 2024

View article titled, 1409-P: Changing Trends in Glucose-Lowering Drug Initiation for Type 2 Diabetes in the Era of Tirzepatide

Meeting Abstracts

33-OR: The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk

HELEN TESFAYE, JULIE M. PAIK, CAROLINE ALIX, SARA JANE CROMER, BRENDAN M. EVERETT, ROBERT GLYNN, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):33-OR

https://doi.org/10.2337/db24-33-OR

Published: 14 June 2024

View article titled, 33-OR: The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk

Meeting Abstracts

915-P: Head-to-Head Comparison of Dapagliflozin vs. Empagliflozin—Cardiovascular and Safety Events

HOJIN SHIN, JULIE M. PAIK, BRENDAN M. EVERETT, ROBERT GLYNN, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):915-P

https://doi.org/10.2337/db24-915-P

Published: 14 June 2024

View article titled, 915-P: Head-to-Head Comparison of Dapagliflozin vs. Empagliflozin—Cardiovascular and Safety Events

Meeting Abstracts

999-P: Trends and Characteristics of Continuous Glucose Monitoring Initiation in Older Adults with Diabetes—A Cohort Study

WAJD ALKABBANI, JULIE M. PAIK, DAE H. KIM, MEDHA MUNSHI, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):999-P

https://doi.org/10.2337/db24-999-P

Published: 14 June 2024

View article titled, 999-P: Trends and Characteristics of Continuous Glucose Monitoring Initiation in Older Adults with Diabetes—A Cohort Study

Meeting Abstracts

1152-P: Treatment Trends in Youth-Onset Type 2 Diabetes—Changing Landscape after GLP-1RA Approval

HOJIN SHIN, JULIE M. PAIK, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):1152-P

https://doi.org/10.2337/db24-1152-P

Published: 14 June 2024

View article titled, 1152-P: Treatment Trends in Youth-Onset Type 2 Diabetes—Changing Landscape after GLP-1RA Approval

Meeting Abstracts

1271-P: Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes

PHYO T. HTOO, HELEN TESFAYE, DEBORAH J. WEXLER, ROBERT GLYNN, NIKLAS SCHMEDT, LISETTE KOENEMAN, JULIE M. PAIK, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):1271-P

https://doi.org/10.2337/db24-1271-P

Published: 14 June 2024

View article titled, 1271-P: Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes

Meeting Abstracts

1266-P: The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk

ELISABETTA PATORNO, HELEN TESFAYE, CAROLINE ALIX, ELYSE C. DICESARE, SARA JANE CROMER, BRENDAN M. EVERETT, ROBERT GLYNN, DEBORAH J. WEXLER, JULIE M. PAIK

Diabetes 2024;73(Supplement_1):1266-P

https://doi.org/10.2337/db24-1266-P

Published: 14 June 2024

View article titled, 1266-P: The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk

Meeting Abstracts

939-P: Safety of Newer Glucose Medications in Adults with Type 2 Diabetes and Low to Moderate CV Risk

JULIE M. PAIK, HELEN TESFAYE, SARA JANE CROMER, ELYSE O. DICESARE, CAROLINE ALIX, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):939-P

https://doi.org/10.2337/db24-939-P

Published: 14 June 2024

View article titled, 939-P: Safety of Newer Glucose Medications in Adults with Type 2 Diabetes and Low to Moderate CV Risk

Meeting Abstracts

796-P: Glucose-Lowering Drugs and Risk of COPD Exacerbations in Adults with Type 2 Diabetes

AVIK RAY, JULIE M. PAIK, WILLIAM B. FELDMAN, SUSHAMA KATTINAKERE SREEDHARA, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):796-P

https://doi.org/10.2337/db24-796-P

Published: 14 June 2024

View article titled, 796-P: Glucose-Lowering Drugs and Risk of COPD Exacerbations in Adults with Type 2 Diabetes

Meeting Abstracts

1403-P: Prescribing Trends of Glucose-Lowering Medications among Adult Kidney Transplant Recipients with Type 2 Diabetes—A U.S. Population-Based Cohort Study

PANUPONG HANSRIVIJIT, ELISABETTA PATORNO, DEBORAH J. WEXLER, REZA ABDI, JULIE M. PAIK

Diabetes 2024;73(Supplement_1):1403-P

https://doi.org/10.2337/db24-1403-P

Published: 14 June 2024

View article titled, 1403-P: Prescribing Trends of Glucose-Lowering Medications among Adult Kidney Transplant Recipients with Type 2 Diabetes—A U.S. Population-Based Cohort Study

Meeting Abstracts

773-P: Trends in Obesity Drug Initiation after the Approval of Tirzepatide in Adults without Type 2 Diabetes

JULIE M. PAIK, JANINNE ORTEGA-MONTIEL, HELEN TESFAYE, CAROLINE ALIX, ELYSE O. DICESARE, SARA JANE CROMER, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):773-P

https://doi.org/10.2337/db24-773-P

Published: 14 June 2024

View article titled, 773-P: Trends in Obesity Drug Initiation after the Approval of Tirzepatide in Adults without Type 2 Diabetes

Meeting Abstracts

772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk

JULIE M. PAIK, HELEN TESFAYE, SARA JANE CROMER, ELYSE O. DICESARE, CAROLINE ALIX, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2024;73(Supplement_1):772-P

https://doi.org/10.2337/db24-772-P

Published: 14 June 2024

View article titled, 772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk

Meeting Abstracts

270-OR: Health Care Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 Diabetes—Results from the EMPRISE study

PHYO T. HTOO, HELEN TESFAYE, SEBASTIAN SCHNEEWEISS, DEBORAH J. WEXLER, ROBERT GLYNN, NIKLAS SCHMEDT, ANOUK DERUAZ-LUYET, LISETTE KOENEMAN, JULIE M. PAIK, ELISABETTA PATORNO

Diabetes 2023;72(Supplement_1):270-OR

https://doi.org/10.2337/db23-270-OR

Published: 20 June 2023

View article titled, 270-OR: Health Care Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 Diabetes—Results from the EMPRISE study

Meeting Abstracts

870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

HELEN TESFAYE, JULIE M. PAIK, LUKE ZABOTKA, PHYO T. HTOO, NIKLAS SCHMEDT, LISETTE KOENEMAN, LEO J. SEMAN, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2023;72(Supplement_1):870-P

https://doi.org/10.2337/db23-870-P

Published: 20 June 2023

View article titled, 870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Meeting Abstracts

269-OR: Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes—Results from the EMPRISE Study

HELEN TESFAYE, PHYO T. HTOO, JULIE M. PAIK, HEIDI ZAKOUL, NIKLAS SCHMEDT, ANOUK DERUAZ-LUYET, LISETTE KOENEMAN, DEBORAH J. WEXLER, ELISABETTA PATORNO

Diabetes 2023;72(Supplement_1):269-OR

https://doi.org/10.2337/db23-269-OR

Published: 20 June 2023

View article titled, 269-OR: Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes—Results from the EMPRISE Study

Meeting Abstracts

1227-P: Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease—Results from the EMPRISE Study

PHYO T. HTOO, ELISABETTA PATORNO, HELEN TESFAYE, DEBORAH J. WEXLER, ROBERT GLYNN, NIKLAS SCHMEDT, LISETTE KOENEMAN, SEBASTIAN SCHNEEWEISS, JULIE M. PAIK

Diabetes 2023;72(Supplement_1):1227-P

https://doi.org/10.2337/db23-1227-P

Published: 20 June 2023

View article titled, 1227-P: Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease—Results from the EMPRISE Study

Meeting Abstracts

1086-P: Cardiovascular Effectiveness of SGLT2 Inhibitors: Head-to-Head Comparisons

DEVIN ABRAHAMI, ELVIRA D’ANDREA, JULIE M. PAIK, DEBORAH J. WEXLER, BRENDAN M. EVERETT, SEOYOUNG C. KIM, ELISABETTA PATORNO

Diabetes 2022;71(Supplement_1):1086-P

https://doi.org/10.2337/db22-1086-P

Published: 01 June 2022

View article titled, 1086-P: Cardiovascular Effectiveness of SGLT2 Inhibitors: Head-to-Head Comparisons

Meeting Abstracts

1079-P: Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

PHYO T. HTOO, HELEN TESFAYE, JULIE M. PAIK, DEBORAH J. WEXLER, MEHDI NAJAFZADEH, ROBERT GLYNN, ANOUK DERUAZ-LUYET, SOULMAZ F. FAZELI FARSANI, LISETTE KOENEMAN, SEBASTIAN SCHNEEWEISS, ELISABETTA PATORNO

Diabetes 2022;71(Supplement_1):1079-P

https://doi.org/10.2337/db22-1079-P

Published: 01 June 2022

View article titled, 1079-P: Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Meeting Abstracts

1082-P: Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes

ALEXANDER KUTZ, CHANDRASEKAR GOPALAKRISHNAN, DAE H. KIM, ELISABETTA PATORNO

Diabetes 2022;71(Supplement_1):1082-P

https://doi.org/10.2337/db22-1082-P

Published: 01 June 2022

View article titled, 1082-P: Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes

NARROW

756-P: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Endoscopy Failure or Aspiration—A Cohort Study

1409-P: Changing Trends in Glucose-Lowering Drug Initiation for Type 2 Diabetes in the Era of Tirzepatide

33-OR: The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk

915-P: Head-to-Head Comparison of Dapagliflozin vs. Empagliflozin—Cardiovascular and Safety Events

999-P: Trends and Characteristics of Continuous Glucose Monitoring Initiation in Older Adults with Diabetes—A Cohort Study

1152-P: Treatment Trends in Youth-Onset Type 2 Diabetes—Changing Landscape after GLP-1RA Approval

1271-P: Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes

1266-P: The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk

939-P: Safety of Newer Glucose Medications in Adults with Type 2 Diabetes and Low to Moderate CV Risk

796-P: Glucose-Lowering Drugs and Risk of COPD Exacerbations in Adults with Type 2 Diabetes

1403-P: Prescribing Trends of Glucose-Lowering Medications among Adult Kidney Transplant Recipients with Type 2 Diabetes—A U.S. Population-Based Cohort Study

773-P: Trends in Obesity Drug Initiation after the Approval of Tirzepatide in Adults without Type 2 Diabetes

772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk

270-OR: Health Care Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 Diabetes—Results from the EMPRISE study

870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

269-OR: Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes—Results from the EMPRISE Study

1227-P: Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease—Results from the EMPRISE Study

1086-P: Cardiovascular Effectiveness of SGLT2 Inhibitors: Head-to-Head Comparisons

1079-P: Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

1082-P: Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only